v3.25.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
ATM facility
Merck Investment Agreement
Tempus Investment Agreement
Common Stock
Common Stock
ATM facility
Common Stock
Merck Investment Agreement
Common Stock
Tempus Investment Agreement
Additional Paid-In Capital
Additional Paid-In Capital
ATM facility
Additional Paid-In Capital
Merck Investment Agreement
Additional Paid-In Capital
Tempus Investment Agreement
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance at Dec. 31, 2022 $ 218,139       $ 5       $ 579,456       $ (912) $ (360,410)
Beginning balance, shares at Dec. 31, 2022         46,707,084                  
Proceeds from sales of common stock, net   $ 3,513               $ 3,513        
Proceeds from sales of common stock, net, shares           1,935,214                
Proceeds from exercise of stock options, shares         8                  
Proceeds from ESPP 1,344               1,344          
Proceeds from ESPP, shares         999,194                  
Restricted stock units vested, shares         839,194                  
Stock-based compensation 14,051               14,051          
Foreign currency translation adjustment 19                       19  
Unrealized gain (loss) on available-for-sale debt securities 671                       671  
Net Income (Loss) (108,296)                         (108,296)
Ending balance at Dec. 31, 2023 129,441       $ 5       598,364       (222) (468,706)
Ending balance, shares at Dec. 31, 2023         50,480,694                  
Proceeds from sales of common stock, net   $ 30,078 $ 49,722 $ 16,605   $ 1 $ 2     $ 30,077 $ 49,720 $ 16,605    
Proceeds from sales of common stock, net, shares           6,660,731 14,044,943 3,500,000            
Exercise of Tempus Warrants, Shares         9,218,800                  
Exercise of Tempus Warrants 46,739       $ 1       46,738          
Proceeds from exercise of stock options 200               200          
Proceeds from exercise of stock options, shares         80,998                  
Proceeds from ESPP 571               571          
Proceeds from ESPP, shares         583,695                  
Restricted stock units vested, shares         601,285                  
Stock-based compensation 10,686               10,686          
Foreign currency translation adjustment 164                       164  
Unrealized gain (loss) on available-for-sale debt securities 35                       35  
Net Income (Loss) (81,284)                         (81,284)
Ending balance at Dec. 31, 2024 $ 202,957       $ 9       $ 752,961       $ (23) $ (549,990)
Ending balance, shares at Dec. 31, 2024         85,171,146